NDAINTRAVENOUSSOLUTION
Approved
Apr 2008
Lifecycle
LOE Approaching
Competitive Pressure
25/100
Clinical Trials
20
Data completeness
5/8 — Partial
LEXISCAN (regadenoson) by Astellas is adenosine receptor agonists [moa]. Approved for adenosine receptor agonist [epc]. First approved in 2008.
Drug data last refreshed 9h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LEXISCAN (regadenoson) is an adenosine receptor agonist administered intravenously that mimics the effects of adenosine to induce coronary vasodilation. It is used as a pharmacologic stress agent for myocardial perfusion imaging in patients unable to exercise. The drug selectively activates A2A adenosine receptors, increasing blood flow to detect ischemia.
LOE Approaching4mo to LOE
Product approaching loss of exclusivity in early 2027 with moderate competitive pressure (25), suggesting contraction of brand team and shift toward efficiency and defensive positioning.
Mechanism of Action
Adenosine Receptor Agonists
Pharmacologic Class:
Adenosine Receptor Agonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Use of Stress-CMR Using Regadenoson and GE-267 in Adult Patients with Known or Suspected Coronary Artery Disease
Started Jun 2025
80 enrolled
Coronary Artery Disease
A Study to Evaluate the Safety and Pharmacokinetics of Regadenoson in Pediatric Patients
Started May 2021
54 enrolled
Myocardial IschemiaCoronary Artery Disease
Use of Lexiscan for Myocardial Stress Perfusion Computed Tomography With a 3rd Generation Dual Source CT System
Started Feb 2016
24 enrolled
Cardiovascular DiseasesCoronary Artery Disease
Accuracy of an Echo-Stress Protocol Using Regadenoson With Speckle Tracking
Started Sep 2014
161 enrolled
Ischemia
Regadenoson for Acute Vasoreactivity Testing in Pulmonary Hypertension
Started Aug 2014
10 enrolled
Pulmonary Hypertension
Worked on LEXISCAN at Astellas? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.